bluebird bio Inc (NASDAQ:BLUE) insider David Davidson sold 4,000 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $202.36, for a total value of $809,440.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
David Davidson also recently made the following trade(s):
- On Monday, January 8th, David Davidson sold 3,522 shares of bluebird bio stock. The shares were sold at an average price of $173.61, for a total value of $611,454.42.
- On Wednesday, January 3rd, David Davidson sold 6,000 shares of bluebird bio stock. The shares were sold at an average price of $180.30, for a total value of $1,081,800.00.
bluebird bio Inc (NASDAQ BLUE) traded down $6.60 during mid-day trading on Monday, reaching $192.30. The company’s stock had a trading volume of 1,040,000 shares, compared to its average volume of 886,654. bluebird bio Inc has a twelve month low of $71.25 and a twelve month high of $222.03. The stock has a market capitalization of $8,810.00, a price-to-earnings ratio of -27.43 and a beta of 2.07.
BLUE has been the topic of several recent research reports. Wedbush restated an “outperform” rating and set a $174.00 price target (up previously from $135.00) on shares of bluebird bio in a report on Thursday, November 2nd. Evercore ISI upgraded bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 price target on the stock in a report on Monday, October 16th. BMO Capital Markets increased their target price on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research note on Monday, October 30th. Maxim Group set a $170.00 target price on bluebird bio and gave the stock a “buy” rating in a research note on Friday, November 17th. Finally, BidaskClub lowered bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. bluebird bio has a consensus rating of “Hold” and an average target price of $161.45.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.